XML 48 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair value of financial instruments and investments (Tables)
12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis
The following represents the fair value using the hierarchy described in Note 2 for the Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of December 31, 2019 and 2018:
 
 
December 31, 2019
 
 
Total
 
Quoted prices
in active
markets for
identical assets
(level 1)
 
Significant
other
observable
inputs
(level 2)
 
Significant
unobservable
inputs
(level 3)
Marketable securities
 
$
398,535

 
$

 
$
398,535

 
$

Equity Investment
 
$
6,194

 
$
6,194

 
$

 
$

Stock appreciation rights liability
 
$
3,186

 
$

 
$

 
$
3,186

Deferred consideration payable
 
$
40,000

 
$

 
$
40,000

 
$

Contingent consideration payable- development and regulatory milestones - Agilis

 
$
290,500

 
$

 
$

 
$
290,500

Contingent consideration payable- net sales milestones and royalties - Agilis
 
$
65,800

 
$

 
$

 
$
65,800

 
 
December 31, 2018
 
 
Total
 
Quoted prices
in active
markets for
identical assets
(level 1)
 
Significant
other
observable
inputs
(level 2)
 
Significant
unobservable
inputs
(level 3)
Marketable securities
 
$
58,088

 
$

 
$
58,088

 
$

Stock appreciation rights liability
 
$
3,814

 
$

 
$

 
$
3,814

Deferred consideration payable
 
$
37,700

 
$

 
$
37,700

 
$

Contingent consideration payable- development and regulatory milestones- Agilis

 
$
257,040

 
$

 
$

 
$
257,040

Contingent consideration payable- net sales milestones and royalties- Agilis
 
$
53,200

 
$

 
$

 
$
53,200


Summary of marketable securities accounted for as available-for-sale securities
The following is a summary of marketable securities accounted for as available-for-sale securities at December 31, 2019 and 2018:
 
 
December 31, 2019
 
 
Amortized
Cost
 
Gross
Unrealized
 
Fair
Value
 
 
 
 
 
 
 
Gains
 
Losses
 
Commercial paper
 
$
157,936

 
$
162

 
$

 
$
158,098

Corporate debt securities
 
188,778

 
576

 
(20
)
 
189,334

Asset-backed securities
 
51,062

 
49

 
(8
)
 
51,103

Total
 
$
397,776

 
$
787

 
$
(28
)
 
$
398,535

 
 
December 31, 2018
 
 
Amortized
Cost
 
Gross
Unrealized
 
Fair
Value
 
 
 
 
 
 
 
Gains
 
Losses
 
Commercial paper
 
$
31,657

 
$
43

 
$
(1
)
 
$
31,699

Corporate debt securities
 
26,399

 

 
(10
)
 
26,389

Total
 
$
58,056

 
$
43

 
$
(11
)
 
$
58,088


Available-for-sale securities, continuous unrealized loss position, fair value
The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of December 31, 2019 are as follows:
 
 
December 31, 2019
 
 
Securities in an unrealized loss position less than 12 months
 
Securities in an unrealized loss position greater than 12 months
 
Total
 
 
Unrealized losses
 
Fair Value
 
Unrealized losses
 
Fair Value
 
Unrealized losses
 
Fair Value
Corporate debt securities
 
$
(20
)
 
$
71,779

 
$

 
$

 
$
(20
)
 
$
71,779

Asset-backed Securities
 
(8
)
 
24,211

 

 

 
(8
)
 
24,211

Total
 
$
(28
)
 
$
95,990

 
$

 
$

 
$
(28
)
 
$
95,990

The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of December 31, 2018 are as follows:
 
 
December 31, 2018
 
 
Securities in an unrealized loss position less than 12 months
 
Securities in an unrealized loss position greater than 12 months
 
Total
 
 
Unrealized losses
 
Fair Value
 
Unrealized losses
 
Fair Value
 
Unrealized losses
 
Fair Value
Commercial paper
 
$
(1
)
 
$
1,993

 
$

 
$

 
$
(1
)
 
$
1,993

Corporate debt securities
 
(7
)
 
14,230

 
(3
)
 
10,087

 
(10
)
 
24,317

Total
 
$
(8
)
 
$
16,223

 
$
(3
)
 
$
10,087

 
$
(11
)
 
$
26,310


Schedule of marketable securities on the balance sheet
Marketable securities on the balance sheet at December 31, 2019 and 2018 mature as follows:
 
 
December 31, 2019
 
 
Less Than
12 Months
 
More Than
12 Months
Commercial paper
 
$
158,098

 
$

Corporate debt securities
 
139,596

 
49,738

Asset-backed Securities
 
44,724

 
6,379

Total Marketable securities
 
$
342,418

 
$
56,117

 
 
December 31, 2018
 
 
Less Than
12 Months
 
More Than
12 Months
Commercial paper
 
$
31,699

 
$

Corporate debt securities
 
26,389

 

Total Marketable securities
 
$
58,088

 
$


Fair value of the Company's Level 3 valuation for warrant liability The table presented below is a summary of changes in the fair value of the Company’s Level 3 valuation for the SARs liability and the contingent consideration payables for the years ended December 31, 2019, and 2018:
 
 
Level 3 liabilities
 
 
 
SARs
 
Contingent consideration payable- development and regulatory milestones - Agilis
 
Contingent consideration payable- net sales milestones and royalties - Agilis
Beginning balance as of December 31, 2017
 
 
$
1,665

 
$

 
$

Additions
 
 

 
263,500

 
27,000

Change in fair value
 
 
4,140

 
(6,460
)
 
26,200

Payments
 
 
$
(1,991
)
 
$

 
$

Ending balance as of December 31, 2018
 
 
3,814

 
257,040

 
53,200

Additions
 
 

 

 

Change in fair value
 
 
3,187

 
33,460

 
12,600

Payments
 
 
(3,815
)
 

 

Ending balance as of December 31, 2019
 
 
$
3,186

 
$
290,500

 
$
65,800


The following significant unobservable inputs were used in the valuation of the SARs liability and the contingent consideration payables for the years ended December 31, 2019 and 2018:
 
 
December 31, 2019
 
 
Fair Value
 
Valuation Technique
 
Unobservable Input
 
Range
SARs
 
$3,186
Option-pricing model
Volatility
28.93%
Risk free interest rate
0.19%
Strike price
$6.76 - $30.86
Fair value of common stock
$48.03
Expected life
0.01 years
Contingent consideration payable- development and regulatory milestones

$290,500
Probability-adjusted discounted cash flow
Potential development and regulatory milestones
$0 - $555 million
Probabilities of success
25% - 94%
Discount rates
2.2% - 4.7%
Projected years of payments
2020 - 2026
Contingent considerable payable- net sales milestones and royalties
$65,800
Option-pricing model with Monte Carlo simulation

Potential net sales milestones
$0 - $150 million
Probabilities of success
25% - 89%
Potential percentage of net sales for royalties
2% - 6%
Discount rate
14.5%
Projected years of payments
2021 - 2038

 
 
December 31, 2018

 
Fair Value
 
Valuation Technique
 
Unobservable Input
 
Range
SARs
 
$3,814
Option-pricing model
Volatility
46.53% - 59.59%
Risk free interest rate
2.44% - 2.63%
Strike price
$6.76 - $30.86
Fair value of common stock
$34.32
Expected life
0.01 - 1.01 years
Contingent consideration payable- development and regulatory milestones

$257,040
Probability-adjusted discounted cash flow
Potential development and regulatory milestones
$0 - $555 million
Probabilities of success
25% - 94%
Discount rates
5.8% - 8.0%
Projected years of payments
2020 - 2026
Contingent considerable payable- net sales milestones and royalties
$53,200
Option-pricing model with Monte Carlo simulation

Potential net sales milestones
$0 - $150 million
Probabilities of success
25% - 89%
Potential percentage of net sales for royalties
2% - 6%
Discount rate
14.0%
Projected years of payments
2021 - 2038